查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球融合切片檢查市場：按根類型、按應用、按產品、最終用戶、按地區 - 預測至 2029 年
市場調查報告書
商品編碼
1618947

全球融合切片檢查市場：按根類型、按應用、按產品、最終用戶、按地區 - 預測至 2029 年

Fusion Biopsy Market by Route Type (Transrectal, Transperineal), Product (Equipment, Consumables), Application (Prostate Cancer), End User (Hospitals), and Region - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 197 Pages | 訂單完成後即時交付

價格

預計2024年全球融合切片檢查市場規模為6.5億美元，預估2029年將達9.1億美元，預測期內複合年成長率為7.1%。

人口老化導致與老齡化相關的健康狀況增加，例如主要影響老年男性的前列腺癌。隨著全球老年人數量的增加，前列腺癌的發生率預計也會增加，導致對融合切片檢查等先進診斷技術的需求增加。需求的成長在歐洲和北美等人口老化嚴重的地區尤其明顯。這些地區的醫療保健系統非常適合使用融合切片檢查等先進技術。

調查範圍
調查年份 2023-2029
基準年 2023年
預測期 2024-2029
考慮單位 金額（百萬美元/十億美元）
按細分市場 按路線類型、按應用、按產品、按最終用戶、按地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東/非洲、海灣合作理事會國家

依產品分類，融合切片檢查市場分為設備和消耗品。設備領域的成長歸因於將高解析度成像與即時超音波相結合以精確定位可疑病變的能力。對這些設備的需求將受到持續的技術進步的推動，例如前列腺癌患病率的上升、微創手術的採用以及人工智慧整合以更好地檢測病變，進一步推動這一領域的成長。

融合切片檢查市場的應用領域以攝護腺癌和其他應用為主。 2023 年，攝護腺癌融合切片檢查市場佔有率最高。前列腺癌的全球高發病率和融合切片檢查在識別這些臨床上重要的惡性的效率是這一高發病率的主要原因。診斷影像技術的改進和早期檢測意識的提高將進一步支持這一領先地位，確保融合切片檢查繼續保持市場領先地位。

該報告研究了全球融合切片檢查市場，包括按根類型、應用、產品、最終用戶、地區和參與市場的公司概況分類的趨勢。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章市場概況

  • 介紹
  • 市場動態
  • 價格分析
  • 價值鏈分析
  • 供應鏈分析
  • 生態系分析
  • 波特五力分析
  • 主要相關人員和採購標準
  • 監管狀況
  • 貿易分析
  • 專利分析
  • 2024年至2026年重大會議及活動
  • 影響客戶業務的趨勢/干擾
  • 技術分析
  • 投資金籌措場景
  • 生成人工智慧對融合切片檢查市場的影響

第6章融合切片檢查市場（按根類型）

  • 介紹
  • 經直腸
  • 經會陰
  • 其他

第7章融合切片檢查市場（按應用）

  • 介紹
  • 攝護腺癌
  • 其他

第8章融合切片檢查市場（按產品）

  • 介紹
  • 裝置
  • 消耗品

第9章融合切片檢查市場（按最終用戶）

  • 介紹
  • 醫院
  • 其他

第10章融合切片檢查市場（按地區）

  • 介紹
  • 北美洲
    • 北美宏觀經濟展望
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲宏觀經濟展望
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 亞太宏觀經濟展望
    • 中國
    • 日本
    • 印度
    • 其他
  • 拉丁美洲
    • 對基礎設施發展缺乏興趣和資源配置不當可能會阻礙市場成長
    • 拉丁美洲和加勒比海地區的宏觀經濟前景
  • 中東/非洲
    • 擴大醫療保健覆蓋範圍和增加醫療保健投資推動市場
    • 中東和非洲宏觀經濟前景
  • 海灣合作理事會國家
    • 醫療保健行業的進步和政府投資的增加推動了市場
    • 海灣合作理事會國家的宏觀經濟前景

第11章競爭格局

  • 概述
  • 主要參與企業的策略/優勢
  • 2021-2023 年收益佔有率分析
  • 2023 年市場佔有率分析
  • 企業評估矩陣：主要參與企業，2023
  • 企業評估矩陣：Start-Ups/小型企業，2023 年
  • 2024年企業評價與財務指標
  • 品牌/產品比較
  • 競爭場景

第12章 公司簡介

  • 主要參與企業
    • KONINKLIJKE PHILIPS NV
    • GE HEALTHCARE
    • KOELIS
    • FUJIFILM HOLDINGS CORPORATION
    • CANON INC.
    • SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    • ESAOTE SPA
    • EIGEN HEALTH
  • 其他公司
    • FOCAL HEALTHCARE
    • MTT GMBH
    • MEDCOM
    • UC-CARE MEDICAL SYSTEMS
    • BIOBOT SURGICAL

第13章附錄

Product Code: MD 9228

The global fusion biopsy market is valued at an estimated 0.65 billion in 2024 and is projected to reach USD 0.91 billion by 2029, at a CAGR of 7.1% during the forecast period. The old population is causing a rise in age-related health conditions, such as prostate cancer, which predominantly affects older men. As these elderly individuals grows globally, the incidence of prostate cancer is also expected to increase leading to increased demand for advanced diagnostic technologies such as fusion biopsy. The increase in demand is especially seen in areas with older populations, like Europe and North America. These regions have healthcare systems that are better able to use advanced technologies like fusion biopsy.

Scope of the Report
Years Considered for the Study2023-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD Million/Billion)
SegmentsBy Route Type, Product, Application, End User, And Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries

"The equipment segment is projected to witness the highest growth rate in the fusion biopsy market, by product, during the forecast period."

Based on product, the fusion biopsy market is segmented into equipment and consumables. The growth of equipment segment is owing to their ability to combine high-resolution imaging with real-time ultrasound for precise targeting of suspicious lesions. The demand for these equipment is fueled by the increasing prevalence of prostate cancer, the adoption of minimally invasive procedures, and ongoing technological advancements, such as AI integration for better lesion detection, further accelerates the growth of this segment.

"In 2023, the prostate cancer segment accounted for the largest share of the fusion biopsy market, by application."

Prostate cancer and other applications make up the application-based segments of the fusion biopsy market. Market share for fusion biopsy was highest in the prostate cancer in 2023. The high incidence of prostate cancer worldwide and the efficiency of fusion biopsy in identifying these clinically relevant malignancies are the primary causes of this high percentage. Improvements in imaging technology and growing awareness of early detection further support this the lead, guaranteeing its sustained market leadership in fusion biopsy.

"The Asia Pacific region is projected to witness highest growth rate in the fusion biopsy market during the forecast period"

The global fusion biopsy market is segmented into six regions - North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. Over the span of the forecast period, the fusion biopsy market is expected to grow at the fastest rate in the Asia Pacific region. The rising healthcare investments, a growing prevalence of cancers like prostate cancer, and a large aging population vulnerable to cancer contribute to the significant market growth in the Aisa Pacific region during the projected period.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 35%, Europe - 31%, Asia Pacific - 22%, Latin America - 9%, Middle East & Africa - 2%, and the GCC Countries - 1%

Lists of Companies Profiled in the Report:

Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), KOELIS (France), FUJIFILM Holdings Corporation (Japan), Eigen Health (US), Focal Healthcare (Canada), Esaote SPA (Italy), MTT GmbH (Germany), MedCom (Germany), UC-CARE Medical Systems (US), Biobot Surgical (Singapore), Canon Inc. (Japan), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)

Research Coverage:

In this report, the fusion biopsy market has been categorized based on product (equipment and consumables), end user (hospitals and other end users), route type (transsrectal, transperineal, and other route types), application (prostate cancer and other applications), and region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries).

Comprehensive information regarding the main drivers, barriers, opportunities, and challenges influencing the fusion biopsy market's expansion is included in detail in this study. An exhaustive study of the key players in the fusion biopsy market has been done to provide insights into their business profile, products offered, noteworthy strategies, collaborations, and other recent activities pertaining to the market.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall fusion biopsy market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, challenges, opportunities, and restaints.

The report provides insights on the following pointers:

  • Analysis of key drivers: (Increasing prevalence of prostate cancer and growing gearitric population, availability of reimbursements and investments by public and private sector, and rising prevalence of minimally invasive surgery), restraints (High cost of fusio biopsy system and alternative methods for fusion biopsy), opportunities (Rise in prevalence of prostate cancer in emerging economies and technological advancements in fusion biopsy devices), and challenges (Paucity of skilled professionals and limited reimbursement in few countries) influencing the growth of the in fusion biopsy market.
  • Product Development/ Innovation: Detailed insights on upcoming technologies, research development activities, and new product launches in the fusion biopsy market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the fusion biopsy market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the fusion biopsy market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), and KOELIS (France) are among others, in the fusion biopsy market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
      • 2.1.2.4 Breakdown of primary interviews
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach 1: Company revenue estimation approach
    • 2.2.2 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 GROWTH RATE ASSUMPTIONS
  • 2.7 RESEARCH LIMITATIONS
    • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.7.2 SCOPE-RELATED LIMITATIONS
  • 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 FUSION BIOPSY MARKET OVERVIEW
  • 4.2 NORTH AMERICA: FUSION BIOPSY MARKET, BY APPLICATION AND COUNTRY (2023)
  • 4.3 FUSION BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 FUSION BIOPSY MARKET: REGIONAL MIX (2024-2029)
  • 4.5 FUSION BIOPSY MARKET: DEVELOPED VS. DEVELOPING MARKETS

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing prevalence of prostate cancer and growing geriatric population
      • 5.2.1.2 Availability of reimbursements and investments by public and private sectors
      • 5.2.1.3 Rising prevalence of minimally invasive surgery
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High costs of fusion biopsy systems
      • 5.2.2.2 Alternative methods for fusion biopsy
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rise in prevalence of prostate cancer in emerging economies
      • 5.2.3.2 Technological advancements in fusion biopsy devices
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Paucity of skilled professionals
      • 5.2.4.2 Limited reimbursement in few countries
  • 5.3 PRICING ANALYSIS
    • 5.3.1 PRICING ANALYSIS, BY REGION
    • 5.3.2 PRICING ANALYSIS, BY PRODUCT
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
    • 5.6.1 FUSION BIOPSY MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • 5.7 PORTER'S FIVE FORCES ANALYSIS
    • 5.7.1 THREAT OF NEW ENTRANTS
    • 5.7.2 THREAT OF SUBSTITUTES
    • 5.7.3 BARGAINING POWER OF BUYERS
    • 5.7.4 BARGAINING POWER OF SUPPLIERS
    • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.8.2 BUYING CRITERIA
  • 5.9 REGULATORY LANDSCAPE
    • 5.9.1 NORTH AMERICA
      • 5.9.1.1 US
      • 5.9.1.2 Canada
    • 5.9.2 EUROPE
    • 5.9.3 ASIA PACIFIC
      • 5.9.3.1 Japan
      • 5.9.3.2 China
      • 5.9.3.3 India
    • 5.9.4 LATIN AMERICA
      • 5.9.4.1 BRAZIL
      • 5.9.4.2 MEXICO
    • 5.9.5 MIDDLE EAST
    • 5.9.6 AFRICA
    • 5.9.7 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10 TRADE ANALYSIS
    • 5.10.1 TRADE ANALYSIS FOR FUSION BIOPSY MARKET
  • 5.11 PATENT ANALYSIS
  • 5.12 KEY CONFERENCES AND EVENTS IN 2024-2026
  • 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.14 TECHNOLOGY ANALYSIS
    • 5.14.1 KEY TECHNOLOGIES
      • 5.14.1.1 MRI-ultrasound fusion imaging
    • 5.14.2 COMPLEMENTARY TECHNOLOGIES
      • 5.14.2.1 Liquid biopsy
        • 5.14.2.1.1 Digital droplet PCR
        • 5.14.2.1.2 Tagged-amplicon deep sequencing
  • 5.15 INVESTMENT & FUNDING SCENARIO
  • 5.16 IMPACT OF GENERATIVE ARTIFICIAL INTELLIGENCE ON FUSION BIOPSY MARKET

6 FUSION BIOPSY MARKET, BY ROUTE TYPE

  • 6.1 INTRODUCTION
  • 6.2 TRANSRECTAL
    • 6.2.1 HEIGHTENED POTENTIAL FOR SERIOUS INFECTIONS TO HINDER MARKET GROWTH
  • 6.3 TRANSPERINEAL
    • 6.3.1 IMPROVED CANCER DETECTION THROUGH COMBINATION OF MRI AND ULTRASOUND TO FUEL MARKET GROWTH
  • 6.4 OTHER ROUTE TYPES

7 FUSION BIOPSY MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 PROSTATE CANCER
    • 7.2.1 PRECISE AND RELIABLE RESULTS OF PROSTATE FUSION BIOPSY TO ACCELERATE MARKET GROWTH
  • 7.3 OTHER APPLICATIONS

8 FUSION BIOPSY MARKET, BY PRODUCT

  • 8.1 INTRODUCTION
  • 8.2 EQUIPMENT
    • 8.2.1 SUBSTANTIAL INITIAL INVESTMENTS TO ENSURE MARKET GROWTH
  • 8.3 CONSUMABLES
    • 8.3.1 INCREASING APPLICATION OF INNOVATIVE TECHNOLOGIES AND METHODOLOGIES TO PROPEL MARKET GROWTH

9 FUSION BIOPSY MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 HOSPITALS
    • 9.2.1 RISING DEMAND FOR QUICK AND ACCURATE DIAGNOSIS TO PROMOTE MARKET GROWTH
  • 9.3 OTHER END USERS

10 FUSION BIOPSY MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 10.2.2 US
      • 10.2.2.1 Funding for cancer research and availability of technologically advanced products to propel market growth
    • 10.2.3 CANADA
      • 10.2.3.1 Surging need for advanced diagnostic solutions to drive market
  • 10.3 EUROPE
    • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 10.3.2 GERMANY
      • 10.3.2.1 Rising healthcare expenditure and increasing incidence of cancer to bolster market growth
    • 10.3.3 UK
      • 10.3.3.1 Enhanced clinical infrastructure to accelerate fusion biopsy adoption
    • 10.3.4 FRANCE
      • 10.3.4.1 Effective reimbursement policies and government support for surgical product manufacturers to augment market
    • 10.3.5 ITALY
      • 10.3.5.1 Rising healthcare demands of geriatric population to support market growth
    • 10.3.6 SPAIN
      • 10.3.6.1 Improved healthcare infrastructure and rising geriatric demographics to boost market
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 10.4.2 CHINA
      • 10.4.2.1 Increasing disposable income of middle-class population and rising diagnostic procedures to boost market
    • 10.4.3 JAPAN
      • 10.4.3.1 Robust healthcare system and surging need for precise early cancer detection to support market growth
    • 10.4.4 INDIA
      • 10.4.4.1 Large patient population and increasing healthcare investments to drive market
    • 10.4.5 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 LOW FOCUS ON INFRASTRUCTURAL IMPROVEMENT AND POOR DISTRIBUTION OF RESOURCES LIKELY TO HINDER MARKET GROWTH
    • 10.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA & CARIBBEAN
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 EXPANDING ACCESS TO HEALTHCARE AND INCREASED HEALTHCARE INVESTMENTS TO PROPEL MARKET
    • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.7 GCC COUNTRIES
    • 10.7.1 ADVANCEMENTS AND INCREASED GOVERNMENT INVESTMENTS IN HEALTHCARE SECTOR TO PROPEL MARKET
    • 10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN FUSION BIOPSY MARKET
  • 11.3 REVENUE SHARE ANALYSIS, 2021-2023
  • 11.4 MARKET SHARE ANALYSIS, 2023
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 11.5.5.1 Company footprint
      • 11.5.5.2 Region footprint
      • 11.5.5.3 Route type footprint
      • 11.5.5.4 Product footprint
      • 11.5.5.5 Application footprint
      • 11.5.5.6 End user footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 11.7 COMPANY VALUATION & FINANCIAL METRICS, 2024
  • 11.8 BRAND/PRODUCT COMPARISON
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT LAUNCHES & APPROVALS
    • 11.9.2 DEALS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
    • 12.1.1 KONINKLIJKE PHILIPS N.V.
      • 12.1.1.1 Business overview
      • 12.1.1.2 Products offered
      • 12.1.1.3 MnM view
        • 12.1.1.3.1 Key strengths
        • 12.1.1.3.2 Strategic choices
        • 12.1.1.3.3 Weaknesses & competitive threats
    • 12.1.2 GE HEALTHCARE
      • 12.1.2.1 Business overview
      • 12.1.2.2 Products offered
      • 12.1.2.3 MnM view
        • 12.1.2.3.1 Right to win
        • 12.1.2.3.2 Strategic choices
        • 12.1.2.3.3 Weaknesses & competitive threats
    • 12.1.3 KOELIS
      • 12.1.3.1 Business overview
      • 12.1.3.2 Products offered
      • 12.1.3.3 Recent developments
        • 12.1.3.3.1 Deals
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Right to win
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses & competitive threats
    • 12.1.4 FUJIFILM HOLDINGS CORPORATION
      • 12.1.4.1 Business overview
      • 12.1.4.2 Products offered
      • 12.1.4.3 Recent developments
        • 12.1.4.3.1 Product launches & approvals
    • 12.1.5 CANON INC.
      • 12.1.5.1 Business overview
      • 12.1.5.2 Products offered
    • 12.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
      • 12.1.6.1 Business overview
      • 12.1.6.2 Products offered
    • 12.1.7 ESAOTE SPA
      • 12.1.7.1 Business overview
      • 12.1.7.2 Products offered
    • 12.1.8 EIGEN HEALTH
      • 12.1.8.1 Business overview
      • 12.1.8.2 Products offered
  • 12.2 OTHER PLAYERS
    • 12.2.1 FOCAL HEALTHCARE
    • 12.2.2 MTT GMBH
    • 12.2.3 MEDCOM
    • 12.2.4 UC-CARE MEDICAL SYSTEMS
    • 12.2.5 BIOBOT SURGICAL

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 RISK ASSESSMENT
  • TABLE 2 PROSTATE CANCER INCIDENCE, BY REGION, 2022
  • TABLE 3 AVERAGE SELLING PRICE TREND OF FUSION BIOPSY PRODUCTS, BY REGION, 2021-2023
  • TABLE 4 PRICING ANALYSIS OF FUSION BIOPSY PRODUCTS, 2021-2023
  • TABLE 5 FUSION BIOPSY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 6 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF FUSION BIOPSY END USERS (%)
  • TABLE 7 KEY BUYING CRITERIA FOR FUSION BIOPSY END USERS
  • TABLE 8 US FDA: MEDICAL DEVICE CLASSIFICATION
  • TABLE 9 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 10 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 11 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
  • TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 IMPORT DATA FOR FUSION BIOPSY MARKET, BY COUNTRY, 2019-2023 (USD MILLION)
  • TABLE 19 EXPORT DATA FOR FUSION BIOPSY MARKET, BY COUNTRY, 2019-2023 (USD MILLION)
  • TABLE 20 FUSION BIOPSY MARKET: KEY CONFERENCES AND EVENTS IN 2024-2026
  • TABLE 21 FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 22 FUSION BIOPSY MARKET FOR TRANSRECTAL ROUTE TYPES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 23 NORTH AMERICA: FUSION BIOPSY MARKET FOR TRANSRECTAL ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 24 EUROPE: FUSION BIOPSY MARKET FOR TRANSRECTAL ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 25 ASIA PACIFIC: FUSION BIOPSY MARKET FOR TRANSRECTAL ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 26 FUSION BIOPSY MARKET FOR TRANSPERINEAL ROUTE TYPES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 27 NORTH AMERICA: FUSION BIOPSY MARKET FOR TRANSPERINEAL ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 28 EUROPE: FUSION BIOPSY MARKET FOR TRANSPERINEAL ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 29 ASIA PACIFIC: FUSION BIOPSY MARKET FOR TRANSPERINEAL ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 30 FUSION BIOPSY MARKET FOR OTHER ROUTE TYPES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 31 NORTH AMERICA: FUSION BIOPSY MARKET FOR OTHER ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 32 EUROPE: FUSION BIOPSY MARKET FOR OTHER ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 33 ASIA PACIFIC: FUSION BIOPSY MARKET FOR OTHER ROUTE TYPES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 34 FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 35 PROSTATE CANCER INCIDENCE, BY REGION, 2022
  • TABLE 36 FUSION BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 37 NORTH AMERICA: FUSION BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 38 EUROPE: FUSION BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 39 ASIA PACIFIC: FUSION BIOPSY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 40 FUSION BIOPSY MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 41 NORTH AMERICA: FUSION BIOPSY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 42 EUROPE: FUSION BIOPSY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: FUSION BIOPSY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 45 KEY PRODUCTS IN FUSION BIOPSY EQUIPMENT MARKET
  • TABLE 46 FUSION BIOPSY MARKET FOR EQUIPMENT, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 47 NORTH AMERICA: FUSION BIOPSY MARKET FOR EQUIPMENT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 48 EUROPE: FUSION BIOPSY MARKET FOR EQUIPMENT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: FUSION BIOPSY MARKET FOR EQUIPMENT, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 50 KEY PRODUCTS IN FUSION BIOPSY CONSUMABLES MARKET
  • TABLE 51 FUSION BIOPSY MARKET FOR CONSUMABLES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 52 NORTH AMERICA: FUSION BIOPSY MARKET FOR CONSUMABLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 53 EUROPE: FUSION BIOPSY MARKET FOR CONSUMABLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 54 ASIA PACIFIC: FUSION BIOPSY MARKET FOR CONSUMABLES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 55 FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 56 FUSION BIOPSY MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 57 NORTH AMERICA: FUSION BIOPSY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 58 EUROPE: FUSION BIOPSY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 59 ASIA PACIFIC: FUSION BIOPSY MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 60 FUSION BIOPSY MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 61 NORTH AMERICA: FUSION BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 62 EUROPE: FUSION BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 63 ASIA PACIFIC: FUSION BIOPSY MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 64 FUSION BIOPSY MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 65 NORTH AMERICA: PROSTATE CANCER INCIDENCE, BY COUNTRY, 2022
  • TABLE 66 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • TABLE 67 NORTH AMERICA: FUSION BIOPSY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 68 NORTH AMERICA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 69 NORTH AMERICA: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 70 NORTH AMERICA: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 71 NORTH AMERICA: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 72 US: NUMBER OF MAGNETIC RESONANCE IMAGING (MRI) EXAMS CONDUCTED, 2022-2029 (NUMBER PER 1,000 PERSONS)
  • TABLE 73 US: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 74 US: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 75 US: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 76 US: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 77 CANADA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 78 CANADA: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 79 CANADA: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 80 CANADA: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 81 EUROPE: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
  • TABLE 82 EUROPE: MACROECONOMIC OUTLOOK
  • TABLE 83 EUROPE: FUSION BIOPSY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 84 EUROPE: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 85 EUROPE: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 86 EUROPE: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 87 EUROPE: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 88 GERMANY: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
  • TABLE 89 GERMANY: NUMBER OF MAGNETIC RESONANCE IMAGING (MRI) EXAMS CONDUCTED, 2022-2029 (NUMBER PER 1,000 PERSONS)
  • TABLE 90 GERMANY: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 91 GERMANY: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 92 GERMANY: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 93 GERMANY: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 94 UK: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
  • TABLE 95 UK: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 96 UK: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 97 UK: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 98 UK: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 99 FRANCE: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
  • TABLE 100 FRANCE: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 101 FRANCE: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 102 FRANCE: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 103 FRANCE: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 104 ITALY: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
  • TABLE 105 ITALY: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 106 ITALY: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 107 ITALY: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 108 ITALY: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 109 SPAIN: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
  • TABLE 110 SPAIN: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 111 SPAIN: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 112 SPAIN: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 113 SPAIN: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 114 REST OF EUROPE: PROSTATE CANCER INCIDENCE, BY COUNTRY, 2022
  • TABLE 115 REST OF EUROPE: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 116 REST OF EUROPE: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 117 REST OF EUROPE: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 118 REST OF EUROPE: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • TABLE 120 ASIA PACIFIC: FUSION BIOPSY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 125 CHINA: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
  • TABLE 126 CHINA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 127 CHINA: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 128 CHINA: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 129 CHINA: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 130 JAPAN: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
  • TABLE 131 JAPAN: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 132 JAPAN: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 133 JAPAN: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 134 JAPAN: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 135 INDIA: CANCER INCIDENCE, BY TYPE, 2022 VS. 2030
  • TABLE 136 INDIA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 137 INDIA: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 138 INDIA: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 139 INDIA: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 140 PROSTATE CANCER INCIDENCE, BY COUNTRY, 2022 VS. 2030
  • TABLE 141 REST OF ASIA PACIFIC: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 142 REST OF ASIA PACIFIC: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 143 REST OF ASIA PACIFIC: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 144 REST OF ASIA PACIFIC: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 145 LATIN AMERICA: PROSTATE CANCER INCIDENCE, 2022
  • TABLE 146 LATIN AMERICA & CARIBBEAN: MACROECONOMIC OUTLOOK
  • TABLE 147 LATIN AMERICA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 148 LATIN AMERICA: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 149 LATIN AMERICA: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 150 LATIN AMERICA: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 151 AFRICA: CANCER INCIDENCE, MORTALITY, AND PREVALENCE, BY CANCER TYPE, 2022
  • TABLE 152 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • TABLE 153 MIDDLE EAST & AFRICA: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 154 MIDDLE EAST & AFRICA: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 155 MIDDLE EAST & AFRICA: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 156 MIDDLE EAST & AFRICA: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 157 GCC COUNTRIES: MACROECONOMIC OUTLOOK
  • TABLE 158 GCC COUNTRIES: FUSION BIOPSY MARKET, BY ROUTE TYPE, 2022-2029 (USD MILLION)
  • TABLE 159 GCC COUNTRIES: FUSION BIOPSY MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 160 GCC COUNTRIES: FUSION BIOPSY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 161 GCC COUNTRIES: FUSION BIOPSY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 162 OVERVIEW OF STRATEGIES ADOPTED BY KEY MARKET PLAYERS
  • TABLE 163 FUSION BIOPSY MARKET: DEGREE OF COMPETITION
  • TABLE 164 FUSION BIOPSY MARKET: COMPANY FOOTPRINT
  • TABLE 165 FUSION BIOPSY MARKET: REGION FOOTPRINT
  • TABLE 166 FUSION BIOPSY MARKET: ROUTE TYPE FOOTPRINT
  • TABLE 167 FUSION BIOPSY MARKET: PRODUCT FOOTPRINT
  • TABLE 168 FUSION BIOPSY MARKET: APPLICATION FOOTPRINT
  • TABLE 169 FUSION BIOPSY MARKET: END USER FOOTPRINT
  • TABLE 170 FUSION BIOPSY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
  • TABLE 171 FUSION BIOPSY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 172 FUSION BIOPSY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MARCH 2024
  • TABLE 173 FUSION BIOPSY MARKET: DEALS, JANUARY 2021-MARCH 2024
  • TABLE 174 KONINKLIJKE PHILIPS N.V.: BUSINESS OVERVIEW
  • TABLE 175 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED
  • TABLE 176 GE HEALTHCARE: BUSINESS OVERVIEW
  • TABLE 177 GE HEALTHCARE: PRODUCTS OFFERED
  • TABLE 178 KOELIS: BUSINESS OVERVIEW
  • TABLE 179 KOELIS: PRODUCT OFFERED
  • TABLE 180 KOELIS: DEALS, JANUARY 2021-MARCH 2024
  • TABLE 181 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
  • TABLE 182 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED
  • TABLE 183 FUJIFILM HOLDINGS CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MARCH 2024
  • TABLE 184 CANON INC.: BUSINESS OVERVIEW
  • TABLE 185 CANON INC.: PRODUCTS OFFERED
  • TABLE 186 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: BUSINESS OVERVIEW
  • TABLE 187 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED
  • TABLE 188 ESAOTE SPA: BUSINESS OVERVIEW
  • TABLE 189 ESAOTE SPA: PRODUCTS OFFERED
  • TABLE 190 EIGEN HEALTH: COMPANY OVERVIEW
  • TABLE 191 EIGEN HEALTH: PRODUCTS OFFERED

List of Figures

  • FIGURE 1 FUSION BIOPSY MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 FUSION BIOPSY MARKET: RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 FUSION BIOPSY MARKET: REVENUE SHARE ANALYSIS
  • FIGURE 6 APPROACH BASED ON PATIENT POPULATION
  • FIGURE 7 APPROACH BASED ON NUMBER OF HOSPITALS
  • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 9 FUSION BIOPSY MARKET: TOP-DOWN APPROACH
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 FUSION BIOPSY MARKET, BY ROUTE TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 FUSION BIOPSY MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 FUSION BIOPSY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 FUSION BIOPSY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 GEOGRAPHICAL SNAPSHOT OF FUSION BIOPSY MARKET
  • FIGURE 16 INCREASING PREVALENCE OF PROSTATE CANCER TO DRIVE MARKET GROWTH
  • FIGURE 17 PROSTATE CANCER SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
  • FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 19 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 20 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
  • FIGURE 21 FUSION BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 VALUE CHAIN ANALYSIS OF FUSION BIOPSY MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • FIGURE 23 FUSION BIOPSY MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 24 FUSION BIOPSY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 25 KEY PLAYERS IN FUSION BIOPSY MARKET ECOSYSTEM
  • FIGURE 26 FUSION BIOPSY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF FUSION BIOPSY END USERS
  • FIGURE 28 KEY BUYING CRITERIA FOR FUSION BIOPSY END USERS
  • FIGURE 29 PATENT ANALYSIS FOR FUSION BIOPSY MARKET, JANUARY 2014-OCTOBER 2024
  • FIGURE 30 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS IN FUSION BIOPSY MARKET
  • FIGURE 31 FUSION BIOPSY MARKET: INVESTMENT & FUNDING SCENARIO
  • FIGURE 32 NORTH AMERICA: FUSION BIOPSY MARKET SNAPSHOT
  • FIGURE 33 ASIA PACIFIC: FUSION BIOPSY MARKET SNAPSHOT
  • FIGURE 34 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN FUSION BIOPSY MARKET, 2021-2023
  • FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN FUSION BIOPSY MARKET (2023)
  • FIGURE 36 FUSION BIOPSY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 37 FUSION BIOPSY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 38 EV/EBITDA OF KEY VENDORS, 2024
  • FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 40 FUSION BIOPSY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 41 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)
  • FIGURE 42 GE HEALTHCARE: COMPANY SNAPSHOT (2023)
  • FIGURE 43 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 44 CANON INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 45 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2022)